header
campaign-image

WHEN YOU SEE IT,
BE PREPARED

Generalized Pustular Psoriasis (GPP) is a rare and potentially life-threatening skin disease distinct from Plaque Psoriasis.1-5 Caused by dysregulation of the IL-36 pathway, GPP flares can affect every aspect of a patient’s life. Effective, fast-acting, GPP-specific therapies are needed to control them.1,2,6-9

Get the facts
SEE THE COLLECTION
Flare Intensity collection

THE UNWEARABLE COLLECTION™

Explore The Unwearable Collection™ to understand the physical pain, isolation, and emotions patients feel during a GPP flare.8-12
SEE THE COLLECTION
GPP Quiz

Take the quiz

HOW MUCH DO YOU KNOW ABOUT GPP? 

BEGIN

IL-36=interleukin-36.

REFERENCES

  1. Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666. doi:10.1136/bmjopen-2020-043666

  2. Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919. doi:10.1080/1744666X.2019.1648209

  3. Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37-42. doi:10.2147/PTT.S181808

  4. Navarini AA, Burden AD, Capon F, et al; for the ERASPEN Network. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. doi:10.1111/jdv.14386

  5. Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-144. doi:10.2147/PTT.S98954

  6. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol. 2015;97(4):645-652. doi:10.1189/jlb.3RI1014-495R

  7. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(77):620-628. doi:10.1056/NEJMoa1013068

  8. Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. doi:10.1080/1744666X.2019.1708193

  9. Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529-541. doi:10.1007/s13555-021-00493-0

  10. Skalicky A, Rentz A, Esser D, Thoma C, Gloede T. Symptom experience of patients with generalized pustular psoriasis (GPP). Value in Health. 2020;23{suppl 1j.j:S345. Abstract PROB9. doi: 10.1016/j.jval.2020.04.1310

  11. Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D; for the IMPROVE Investigators. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006;154(5):844-849.doi:10.1111/j.1365-2133.2005.07071

  12. Kotowsky N, Gao R, Singer D, Garry E, Golembesky AK. Healthcare resource utilization (HCRU) in patients with generalized pustular psoriasis (GPP): a claims database study. Value in Health. 2020;23(suppl 1):S333-S334. Abstract PRO29. doi:10.1016/j.jval.2020.04.1257

  13. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109-120. doi:10.1016/j.jaci.2016.08.056